Anastrozole
Generic Name: anastrozole
Brand Names:
Arimidex
Anastrozole is a non-steroidal aromatase inhibitor available as 1 mg tablets for oral administration. Used in the treatment of breast cancer in postmenopausal women.
Overview
Anastrozole is a non-steroidal aromatase inhibitor available as 1 mg tablets for oral administration. Used in the treatment of breast cancer in postmenopausal women.
Uses
Indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, first-line treatment of postmenopausal women with hormone receptor-positive or unknown locally advanced or metastatic breast cancer, and treatment of advanced breast cancer with disease progression following tamoxifen therapy.
Dosage
One 1 mg tablet taken once daily. Can be taken with or without food. For advanced breast cancer, continue until tumor progression. For adjuvant treatment, the ATAC trial used five-year administration. No adjustment needed for renal impairment or elderly patients.
Side Effects
Common reactions include hot flashes (36%), musculoskeletal events (36%), fatigue (19%), and mood disturbances (19%). Serious but rare reactions include skin lesions, allergic reactions with facial swelling, and liver function changes.
Interactions
Do not combine with tamoxifen; no additional benefit demonstrated. Avoid estrogen-containing products as they may diminish activity. Warfarin interaction unlikely; cytochrome P450 inhibition minimal.
Warnings
Increased ischemic cardiovascular events in women with pre-existing heart disease. Decreased bone mineral density. Elevated cholesterol possible. Contraindicated in patients with hypersensitivity to the drug. Reactions include anaphylaxis, angioedema, and urticaria.
Pregnancy
May cause fetal harm when administered to a pregnant woman. Animal studies showed embryo-fetal toxicities. Do not breastfeed during treatment and for 2 weeks after final dose.
Storage
White, biconvex, film-coated tablets containing 1 mg of anastrozole.
Frequently Asked Questions
What is Anastrozole used for?▼
Indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, first-line treatment of postmenopausal women with hormone receptor-positive or unknown locally advanced or metastatic breast cancer, and treatment of advanced breast cancer with disease progression following tamoxifen therapy.
What are the side effects of Anastrozole?▼
Common reactions include hot flashes (36%), musculoskeletal events (36%), fatigue (19%), and mood disturbances (19%). Serious but rare reactions include skin lesions, allergic reactions with facial swelling, and liver function changes.
Can I take Anastrozole during pregnancy?▼
May cause fetal harm when administered to a pregnant woman. Animal studies showed embryo-fetal toxicities. Do not breastfeed during treatment and for 2 weeks after final dose.
What are the important warnings for Anastrozole?▼
Increased ischemic cardiovascular events in women with pre-existing heart disease. Decreased bone mineral density. Elevated cholesterol possible. Contraindicated in patients with hypersensitivity to the drug. Reactions include anaphylaxis, angioedema, and urticaria.
Related Medications
Vitamin C, Zinc, Arnica Montana Extract, Bromelain, Diosmin, Rutin, Citrus Bioflavonoids, Hesperidin Methyl Chalcone
vitamin c, zinc, arnica montana extract, bromelain, diosmin, rutin, citrus bioflavonoids, hesperidin methyl chalcone
DESCRIPTION: Active Ingredients Each tablet contains: Vitamin C (as Sodium Ascorbate) ...............................................................120 mg Zinc (as Zinc Picolinate) ...............................................................................10 mg Arnica Montana Extract 10:1 (equivalent to 500 mg Arnica Montana Powder) ...50 mg Bromelain 2400 GDU/g (from Pineapple) ...................................................400 mg Diosmin (Citrus Aurantium) Fruit Extract...............
Atropine Sulfate Monohydrate
atropine sulfate monohydrate
11 DESCRIPTION Atropine Sulfate Injection, USP is a sterile, nonpyrogenic, isotonic, clear colorless solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. It is administered parenterally by subcutaneous, intramuscular or intravenous injection. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg. May contain sulfuric acid for pH adjustment. pH 3.5 (3.0 to 3.8).
Ranibizumab-eqrn
ranibizumab-eqrn
Vascular Endothelial Growth Factor Inhibitor [EPC]
11 DESCRIPTION Ranibizumab-eqrn is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab-eqrn binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab-eqrn, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.